Tirzepatide Enters the Field of Weight Loss and Will Achieve a 'Small Goal' of Over 10 Billion US Dollars.

Eli Lilly announced the clinical trial results at the 82nd annual meeting of the American Diabetes Association (ADA) in New Orleans on Saturday (June 4), and was also published in the New England Journal of Medicine (NEJM) on the same day. superior.

The specific findings of the SURMOUNT-1 trial are as follows:

Subjects in the tirzepatide group lost an average of 16.0% (35 lbs or 16kg, 5mg), 21.4% (49 lbs or 22kg, 10mg) and 22.5% (52 lbs or 24kg, 15mg) compared to 2.4% in the placebo group (2.4%). , 5 lbs or 2 kg). In addition, 89% (5mg) and 96% (10mg and 15mg) of subjects in the tirzepatide group achieved a weight loss of at least 5% compared to 28% in the placebo group.

All three doses of tirzepatide met all key secondary endpoints of efficacy estimates at 72 weeks of treatment, including:

Percentages of subjects who lost at least 10% body weight: 73% (5mg), 86% (10mg) and 90% (15mg) compared to 14% in the placebo group.

Percentages of subjects who lost at least 15% body weight: 50% (5mg), 74% (10mg) and 78% (15mg) compared to 6.0% in the placebo group.

Percentages of subjects who lost at least 20% body weight: 32% (5mg), 55% (10mg) and 63% (15mg) compared to 1.3% in the placebo group.

Changes in waist circumference from baseline: -14.6cm (5mg), -19.4cm (10mg) and -19.9cm (15mg) compared to -3.4cm in the placebo group.

All three doses of tirzepatide met an additional secondary endpoint at 72 weeks of treatment, measuring the percentage of subjects who lost at least 25% body weight: 16.5% (5mg), 35% (10mg) and 39.7% (15mg) , compared with 0.3% in the placebo group.

Subjects on tirzepatide also had approximately three times less fat mass percentage than lean body mass (33.9% reduction in fat mass versus 10.9% reduction in lean body mass).

Previously, Evaluate Vantage predicted that tirzepatide would generate $4.9 billion in sales by 2026.

With good data, and Eli Lilly's experience in metabolic diseases, tirzepatide may soon achieve the "small target" of more than 10 billion US dollars in sales.